Matthew Metzger
VP, US Ops Oxford BioTherapeutics Ltd
Matthew joined Oxford Biotherapeutics in 2022 and has since been dedicated primarily to external innovation, coordinating and delivering target validation data for partnership programs and business development, developing content and strategies for future partnerships. Currently, he serves as the Alliance and Program Manager of the preclinical programs for both the Roche and Zymeworks collaborations. Additionally, he oversees the internal ADC and bispecific development pipeline. He completed grad school at UC Berkeley and brings years of experience in early-stage biotech startups.
Seminars
Thursday 10th September 2026
From Platform Potential to Deal Reality: Aligning Modality, Targets & Evidence
11:30 am
- How much impact has AI/multi-modal data had on current approaches to drug discovery and translational drug development?
- How are we are validating new, and assessing novel versus de-risked targets?
- What type of clinical data would lead the field to reassess assumptions on a target?
